GlassScriptPhysician profile
Clyde H Williams
NPI 1548329634
$2,334.11
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,723 · 2020: $447 · 2021: $88.10 · 2022: $76.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $295.60 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $289.52 | 2019-2021 | |
| Genentech USA, INC. | $253.42 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $216.74 | 2019-2022 | |
| Grifols USA, LLC | $167.89 | 2019-2020 | |
| Insmed, INC. | $116.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.13 | 2019-2020 | |
| Glaxosmithkline, LLC. | $101.08 | 2019 | |
| Sunovion Pharmaceuticals INC. | $97.84 | 2019-2020 | |
| Shire North American Group INC | $84.93 | 2019 | |
| United Therapeutics Corporation | $62.50 | 2019-2020 | |
| Genzyme Corporation | $60.97 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.97 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $58.51 | 2019 | |
| Allergan, INC. | $49.25 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $47.45 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.52 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $30.04 | 2019 | |
| Portola Pharmaceuticals, LLC | $28.35 | 2019 | |
| Alexion Pharmaceuticals, INC. | $27.53 | 2020 | |
| Philips North America LLC | $26.35 | 2019 | |
| Ucb, INC. | $23.71 | 2019 | |
| Merck Sharp & Dohme LLC | $22.96 | 2019 | |
| Biogen, INC. | $19.80 | 2019 | |
| Pfizer INC. | $15.10 | 2019 | |
| Gilead Sciences, INC. | $14.09 | 2019 | |
| Aytu Biopharma, INC. | $13.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clyde Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.